Prosecution Insights
Last updated: April 19, 2026
Application No. 18/259,461

Medical Graft Devices And Methods Of Making Thereof

Non-Final OA §102§103
Filed
Jun 27, 2023
Examiner
FIEBIG, RUSSELL G
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Acell Inc.
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
3y 1m
To Grant
89%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allow Rate
546 granted / 870 resolved
+2.8% vs TC avg
Strong +26% interview lift
Without
With
+25.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
48 currently pending
Career history
918
Total Applications
across all art units

Statute-Specific Performance

§101
13.1%
-26.9% vs TC avg
§103
38.8%
-1.2% vs TC avg
§102
9.2%
-30.8% vs TC avg
§112
28.4%
-11.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 870 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s election without traverse of Group II, claims 11-19, in the reply filed on 11 November 2025 is acknowledged. Status of the Claims Claims 1-10 and 20 have been withdrawn. Claims 11-19 are presented for examination on the merits. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 11-14 and 16-19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by McAlexander et al. (US2007/0166395). McAlexander discloses medical graft products, including multilaminate, having two or more regions with difference properties (porosity, strength). A hydrated ECM material is lyophilized while being shielded, covered or compressed [0006,0021]. The remoldable material can be first freezed before being lyophilized [0029], especially the freezing step take place while compressing parts of the laminated material [0039-0044]. The covering material can be Teflon or acetyl resin or a suitable fabric [0040], after the covering is complete, the hydrated material is frozen. The final construct is characterized by collapsed area (Fig.2-7) corresponding to the compressed ECM and more open matrix (no compression during the process). The construct can present a latice pattern (crisscross or crosshatch for example [0038], the compression step takes place by compressing the structure (multilayer) between plastic or metallic segments [0037],[0042]. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 11-19 are rejected under 35 U.S.C. 103 as being unpatentable over McAlexander et al. (US2007/0166395) and Dhanaraj et al. (US2015/0258142) and Ward et al. (US2020/0188077). McAlexander et al. is cited for the teaching put forth above. Dhanaraj et al. discloses : a medical graft device made of ECM : decellularized pleural membranes (example 1) were laminated together, various layers of membranes being placed one above each other (up to 4 layers). Below and above the laminated construct, Teflon sheet were placed and then the construct was laminated under vacuum while applying pressure (example 3). A knitted mesh could also be placed between the layers 2 and 3 of the laminate [0044]. After the step of lamination, the construct was further lyophilized (example 4). Ward et al. discloses a tissue graft comprising two or more layers of ECM [0018] without the use of any synthetic material for holding the layers together [0015]. Layers are interlocked with each other by a system of holes and lugs [0017,0019,0022],[0063]. After the lamination step (not further defined), the construct is removed from the mold and can eventually be further lyophilized [0099]. It would have been obvious to one of ordinary skill in the art at the time filing date of the instant Application to make a medical graft device employing the steps of the claimed method which appear to be commonly-employed techniques as taught by the cited references. In KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), the Supreme Court emphasized a flexible approach to the obviousness question, stating that the analysis under 35 U.S.C. § 103 "need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ." Id. at 418; see also id. at 421 ("A person of ordinary skill is... a person of ordinary creativity, not an automaton."). In KSR, the Supreme Court indicated that the obviousness analysis should consider the “background knowledge possessed by a person having ordinary skill in the art.” KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398 (2007). Under KSR, information deemed within PHOSITA’s general knowledge is more powerful than that found buried in a prior art reference because we assume that PHOSITA would consider using their general knowledge in combination with the prior art — even absent any express motivation to do so. Under 35 U.S.C. § 103, the obviousness inquiry turns not only on the prior art, but whether “the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious . . . to a person having ordinary skill in the art to which the claimed invention pertains.” 35 U.S.C. § 103. Regardless of the tribunal, the inquiry into whether any “differences” between the invention and the prior art would have rendered the invention obvious to a skilled artisan necessarily depends on such artisan’s knowledge. While cited references fail to explicitly disclose that the sheets are in a specific orientation i.e., a staggered orientation or a cross-bar configuration, such adjustment of these and/or other particular conventional working conditions is deemed merely a matter of judicious selection, design choice, and routine optimization which is well within the purview of the skilled artisan. As there is a finite number of orientations of the two sheets, it would have been well within the purview of the skilled practitioner to employ an number of possibilities including staggered and cross-bar configuration with a reasonable expectation of success. Accordingly, the instant claims, in the range of proportions where no unexpected results are observed, would have been obvious to one of ordinary skill having the above cited references before him/her. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUSSELL G FIEBIG whose telephone number is (571)270-5366. The examiner can normally be reached M-F 8-4. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Terry McKelvey can be reached at 5712720775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUSSELL G FIEBIG/ Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Jun 27, 2023
Application Filed
Dec 22, 2025
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589120
METHODS OF TREATING EPIDERMOLYSIS BULLOSA WITH CELL-FREE AMNIOTIC FLUID COMPOSITIONS
2y 5m to grant Granted Mar 31, 2026
Patent 12569594
DECELLULARIZED TENDON MATRIX METHODS AND USES THEREOF
2y 5m to grant Granted Mar 10, 2026
Patent 12569518
CARTILAGE TISSUE
2y 5m to grant Granted Mar 10, 2026
Patent 12569528
METHODS FOR MAKING BOTANICAL EXTRACT COMPOSITION
2y 5m to grant Granted Mar 10, 2026
Patent 12558383
AMERICAN COCKROACH EXTRACT, PREPARATION THEREOF, PREPARATION METHODS THEREFOR AND APPLICATIONS THEREOF
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
89%
With Interview (+25.8%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 870 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month